Ruxolitinib, a Janus kinase inhibitor, is associated with severe withdrawal phenomena. Adequate tapering is often underemphasized in surgical emergencies and can complicate the postoperative course. We present a case of acute ruxolitinib withdrawal in a gentleman undergoing emergency cardiac surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201970 | PMC |
| http://dx.doi.org/10.1093/icvts/ivac143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.
Leukemia
December 2024
Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
CRLF2 rearrangements occur in >50% of Ph-like and Down syndrome (DS)-associated B-acute lymphoblastic leukemia (ALL) and induce constitutive kinase signaling targetable by the JAK1/2 inhibitor ruxolitinib under current clinical investigation. While chimeric antigen receptor T cell (CART) immunotherapies have achieved remarkable remission rates in children with relapsed/refractory B-ALL, ~50% of CD19CART-treated patients relapse again, many with CD19 antigen loss. We previously reported preclinical activity of thymic stromal lymphopoietin receptor-targeted cellular immunotherapy (TSLPRCART) against CRLF2-overexpressing ALL as an alternative approach.
View Article and Find Full Text PDF0JAK Inhibitor Withdrawal Causes a Transient Proinflammatory Cascade: A Potential Mechanism for Major Adverse Cardiac Events.
bioRxiv
September 2024
Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Article Synopsis
- The study aimed to assess how stopping JAK1/2 inhibitors (JAKinibs) affects the JAK/STAT signaling pathway in systemic rheumatic diseases, particularly in patients with rheumatoid arthritis.
- Researchers conducted experiments in the lab and on patients, demonstrating that Type I JAKinibs (like ruxolitinib and baricitinib) lead to significant increases in certain signaling proteins when administered, but show a rapid increase of these proteins after the drugs are stopped.
- The findings suggest that withdrawing Type I JAKinibs can lead to heightened inflammatory responses and may contribute to serious cardiac issues, while Type II JAKinibs do not have these effects.
Topical anti-inflammatory treatments for eczema: network meta-analysis.
Cochrane Database Syst Rev
August 2024
National Heart & Lung Institute, Section of Inflammation and Repair, Imperial College London, London, UK.
Article Synopsis
- Eczema is a widespread skin condition with no current prevention or cure, and existing treatments aim to control symptoms without clear consensus on their effectiveness and safety.
- This study aims to compare and rank different topical anti-inflammatory treatments for eczema through a network meta-analysis of randomized controlled trials (RCTs).
- The analysis focuses on various outcomes, including symptom relief, safety, quality of life, and withdrawal rates, while excluding certain types of eczema and treatments not related to topical anti-inflammatories.
Topical steroid withdrawal treated with ruxolitinib cream.
JAAD Case Rep
June 2024
Department of Dermatology, Oregon Health & Science University, Portland, Oregon.
Case Report: Infectious prophylaxis in hematological malignancies.
Front Oncol
May 2023
Department of Translational and Precision Medicine, Policlinico Umberto I, La Sapienza University of Rome, Rome, Italy.
Article Synopsis
- Patients with blood cancers and a history of hepatitis B face a risk of the virus reactivating, especially when treated with the drug ruxolitinib, which is used for myeloproliferative neoplasms.
- Despite the moderate reactivation risk (1-10%) during ruxolitinib treatment, there are no strong guidelines for HBV prevention in these patients.
- The report details a case of a patient with primary myelofibrosis who experienced HBV reactivation after stopping their preventive medication, highlighting the need for ongoing HBV protection when using ruxolitinib.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!